Display options
Cite
Sparano JA, Goldstein LJ, Childs BH, et al. Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin Cancer Res. 2009;15(24):7693-7700doi: 10.1158/1078-0432.CCR-09-1450.
Sparano, J. A., Goldstein, L. J., Childs, B. H., Shak, S., Brassard, D., Badve, S., Baehner, F. L., Bugarini, R., Rowley, S., Perez, E., Shulman, L. N., Martino, S., Davidson, N. E., Sledge, G. W., & Gray, R. (2009). Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 15(24), 7693-7700. https://doi.org/10.1158/1078-0432.CCR-09-1450
Sparano, Joseph A, et al. "Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 15,24 (2009): 7693-7700. doi: https://doi.org/10.1158/1078-0432.CCR-09-1450
Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez E, Shulman LN, Martino S, Davidson NE, Sledge GW, Gray R. Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin Cancer Res. 2009 Dec 15;15(24):7693-7700. doi: 10.1158/1078-0432.CCR-09-1450. PMID: 19996222; PMCID: PMC3396025.
Copy Download .nbib Format: NLM
Share it on

Clin Cancer Res. 2009 Dec 15;15(24):7693-7700. doi: 10.1158/1078-0432.CCR-09-1450.

Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Joseph A Sparano, Lori J Goldstein, Barrett H Childs, Steven Shak, Diana Brassard, Sunil Badve, Frederick L Baehner, Roberto Bugarini, Steve Rowley, Edith Perez, Lawrence N Shulman, Silvana Martino, Nancy E Davidson, George W Sledge, Robert Gray

Affiliations

  1. Authors' Affiliations: Eastern Cooperative Oncology Group, Brookline, Massachusetts; Sanofi-Aventis, Bridgewater, New Jersey; Genomic Health, Inc., Redwood City, California; North Central Cancer Treatment Group, Rochester, Minnesota; Cancer and Leukemia Group B, Chicago, Illinois; and Southwest Oncology Group, Ann Arbor, Michigan.

PMID: 19996222 PMCID: PMC3396025 DOI: 10.1158/1078-0432.CCR-09-1450

Abstract

PURPOSE: To perform an exploratory analysis of the relationship between gene expression and recurrence in operable hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-normal breast cancer patients treated with adjuvant doxorubicin-containing chemotherapy. EXPERIMENTAL DESIGN: RNA was extracted from archived tumor samples derived from 378 patients with stage I to III HR-positive, HER2-normal breast cancer and analyzed by reverse transcription-PCR for a panel of 374 genes, including the 21-gene recurrence score (RS). Patients were randomized to receive adjuvant doxorubicin plus cyclophosphamide or docetaxel in trial E2197, with no difference in recurrence seen in the treatment arms. All available recurrent cases were selected plus a nonrecurrent cohort. Cox proportional hazard models were used to identify relationships between gene expression and recurrence. RESULTS: TOP2A expression exhibited the strongest association with increased recurrence risk (P = 0.01), and was significantly associated with recurrence (P = 0.008) in a multivariate analysis adjusted for clinicopathologic features. Elevated TOP2A expression above the median was associated with a 2.6-fold increase (95% confidence interval, 1.3-5.2; P = 0.008) in risk of recurrence if the RS was <18, and a 2.0-fold increase (95% confidence interval, 1.2-3.2, P = 0.003) if there was an intermediate RS of 18 to 30. CONCLUSIONS: In patients with HR-positive, HER2-normal breast cancer, a population known to have a low incidence of TOP2A gene alterations thought to be predictive of anthracycline benefit, there is a range of TOP2A RNA expression that is strongly associated with recurrence after adjuvant anthracyclines, which provides information complementary to RS, indicating that it merits further evaluation as a prognostic and predictive marker. (Clin Cancer Res 2009;15(24):7693-700).

References

  1. J Clin Oncol. 1999 May;17(5):1474-81 - PubMed
  2. J Clin Oncol. 2007 May 20;25(15):2127-32 - PubMed
  3. Lifetime Data Anal. 2000 Mar;6(1):39-58 - PubMed
  4. Clin Breast Cancer. 2006 Oct;7(4):347-50 - PubMed
  5. J Clin Oncol. 2006 Aug 10;24(23):3726-34 - PubMed
  6. Lancet. 2005 May 14-20;365(9472):1687-717 - PubMed
  7. Anticancer Drug Des. 1990 Nov;5(4):307-17 - PubMed
  8. J Clin Oncol. 2008 May 20;26(15):2473-81 - PubMed
  9. J Clin Oncol. 2005 Jan 20;23(3):619-29 - PubMed
  10. J Clin Oncol. 2008 Sep 1;26(25):4092-9 - PubMed
  11. J Clin Oncol. 2006 Jun 1;24(16):2428-36 - PubMed
  12. Am J Pathol. 2004 Jan;164(1):35-42 - PubMed
  13. Arch Pathol Lab Med. 2007;131(1):18-43 - PubMed
  14. J Clin Oncol. 2008 Sep 1;26(25):4063-71 - PubMed
  15. Cancer. 2006 Jun 1;106(11):2337-44 - PubMed
  16. N Engl J Med. 2004 Dec 30;351(27):2817-26 - PubMed
  17. Stat Med. 2007 Oct 30;26(24):4428-40 - PubMed
  18. J Natl Cancer Inst. 2008 Jan 2;100(1):14-20 - PubMed
  19. J Clin Oncol. 2006 Dec 1;24(34):5381-7 - PubMed
  20. J Clin Oncol. 2008 Feb 10;26(5):736-44 - PubMed
  21. Breast Cancer Res Treat. 2009 Feb;113(3):457-66 - PubMed
  22. N Engl J Med. 2001 Jun 28;344(26):1997-2008 - PubMed
  23. Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3089-94 - PubMed
  24. Lifetime Data Anal. 2009 Mar;15(1):24-40 - PubMed
  25. J Clin Oncol. 2008 Feb 10;26(5):721-8 - PubMed
  26. N Engl J Med. 2005 Oct 20;353(16):1673-84 - PubMed
  27. Clin Cancer Res. 2003 Sep 15;9(11):4116-24 - PubMed
  28. Clin Cancer Res. 2003 Sep 15;9(11):4165-71 - PubMed

Publication Types

Grant support